|
1
|
Isakoff MS, Bielack SS, Meltzer P and
Gorlick R: Osteosarcoma: Current treatment and a collaborative
pathway to success. J Clin Oncol. 33:3029–3035. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Luetke A, Meyers PA, Lewis I and Juergens
H: Osteosarcoma treatment - where do we stand? A state of the art
review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Azizi M, Teimoori-Toolabi L, Arzanani MK,
Azadmanesh K, Fard-Esfahani P and Zeinali S: MicroRNA-148b and
microRNA-152 reactivate tumor suppressor genes through suppression
of DNA methyltransferase-1 gene in pancreatic cancer cell lines.
Cancer Biol Ther. 15:419–427. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang JG, Shi Y, Hong DF, Song M, Huang D,
Wang CY and Zhao G: MiR-148b suppresses cell proliferation and
invasion in hepatocellular carcinoma by targeting WNT1/β-catenin
pathway. Sci Rep. 5:80872015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Borel F, Konstantinova P and Jansen PL:
Diagnostic and therapeutic potential of miRNA signatures in
patients with hepatocellular carcinoma. J Hepatol. 56:1371–1383.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu Q, Xu Y, Wei S, Gao W, Chen L, Zhou T,
Wang Z, Ying M and Zheng Q: miRNA-148b suppresses hepatic cancer
stem cell by targeting neuropilin-1. Biosci Rep. 35:e002292015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang JS, Li BJ, Lu HW, Chen Y, Lu C, Zhu
RX, Liu SH, Yi QT, Li J and Song CH: Serum miR-152, miR-148a,
miR-148b, and miR-21 as novel biomarkers in non-small cell lung
cancer screening. Tumour Biol. 36:3035–3042. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li T, Yin J, Yuan L, Wang S, Yang L, Du X
and Lu J: Downregulation of microRNA-139 is associated with
hepatocellular carcinoma risk and short-term survival. Oncol Rep.
31:1699–1706. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen X, Bahrami A, Pappo A, Easton J,
Dalton J, Hedlund E, Ellison D, Shurtleff S, Wu G, Wei L, et al:
St. Jude Children's Research Hospital–Washington University
Pediatric Cancer Genome Project: Recurrent somatic structural
variations contribute to tumorigenesis in pediatric osteosarcoma.
Cell Rep. 7:104–112. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cheng D, Qiu X, Zhuang M, Zhu C, Zou H and
Liu Z: MicroRNAs with prognostic significance in osteosarcoma: A
systemic review and meta-analysis. Oncotarget. 8:81062–81074. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang Z and Cai H, Lin L, Tang M and Cai H:
Upregulated expression of microRNA-214 is linked to tumor
progression and adverse prognosis in pediatric osteosarcoma.
Pediatr Blood Cancer. 61:206–210. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu X, Zhong D, Gao Q, Zhai W, Ding Z and
Wu J: MicroRNA-34a inhibits human osteosarcoma proliferation by
downregulating ether à go-go 1 expression. Int J Med Sci.
10:676–682. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cote GA, Gore AJ, McElyea SD, Heathers LE,
Xu H, Sherman S and Korc M: A pilot study to develop a diagnostic
test for pancreatic ductal adenocarcinoma based on differential
expression of select miRNA in plasma and bile. Am J Gastroenterol.
109:1942–1952. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dahlmans D, Houzelle A, Schrauwen P and
Hoeks J: Mitochondrial dynamics, quality control and miRNA
regulation in skeletal muscle: Implications for obesity and related
metabolic disease. Clin Sci (Lond). 130:843–852. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu M, Ye X, Wang S, Li Q, Lai Y and Yi Y:
MicroRNA-148b suppresses proliferation, migration, and invasion of
nasopharyngeal carcinoma cells by targeting metastasis-associated
gene 2. OncoTargets Ther. 10:2815–2822. 2017. View Article : Google Scholar
|
|
16
|
Drakaki A, Hatziapostolou M, Polytarchou
C, Vorvis C, Poultsides GA, Souglakos J, Georgoulias V and
Iliopoulos D: Functional microRNA high throughput screening reveals
miR-9 as a central regulator of liver oncogenesis by affecting the
PPARA-CDH1 pathway. BMC Cancer. 15:5422015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang JS, Li BJ, Lu HW, Chen Y, Lu C, Zhu
RX, Liu SH, Yi QT, Li J and Song CH: Serum miR-152, miR-148a,
miR-148b, and miR-21 as novel biomarkers in non-small cell lung
cancer screening. Tumour Biol. 36:3035–3042. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ge H, Li B, Hu WX, Li RJ, Jin H, Gao MM
and Ding CM: MicroRNA-148b is down-regulated in non-small cell lung
cancer and associated with poor survival. Int J Clin Exp Pathol.
8:800–805. 2015.PubMed/NCBI
|
|
19
|
Josefsson A, Hobbs R, Mauxion T, Frey E,
Terezakis S, Meyer C, Loeb D and Sgouros G: Combined treatment
planning and therapy using 153Sm-EDTMP RPT with XRT in pediatric
metastatic osteosarcoma patients. J Nucl Med. 56:3412015.
|
|
20
|
Xu YF, Jiang SJ, Wang YQ, Yao YW and Liu
YX: A survival analysis and treatment outcomes of 131 cases of
osteosarcoma treated with high-dose methotrexate multidrug
chemotherapy. Int J Clin Exp Med. 9:8465–8473. 2016.
|
